PPA
NVRO

Parametric Portfolio Associates’s NEVRO CORP. NVRO Stock Holding History

Parametric Portfolio Associates’s Portfolio NVRO Stock Details NVRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$3.62M Buy
49,990
+5,539
+12% +$399K ﹤0.01% 2072
2021
Q4 		$3.6M Buy
44,451
+6,664
+18% +$668K ﹤0.01% 2086
2021
Q3 		$4.4M Buy
37,787
+4,397
+13% +$576K ﹤0.01% 1926
2021
Q2 		$5.54M Buy
33,390
+337
+1% +$52.6K ﹤0.01% 1782
2021
Q1 		$4.61M Sell
33,053
-1,588
-5% -$259K ﹤0.01% 2235
2020
Q4 		$6M Sell
34,641
-4,633
-12% -$750K ﹤0.01% 1954
2020
Q3 		$5.47M Sell
39,274
-145
-0.4% -$19.4K ﹤0.01% 1835
2020
Q2 		$4.71M Sell
39,419
-5,978
-13% -$709K ﹤0.01% 1916
2020
Q1 		$4.54M Buy
45,397
+11,905
+36% +$1.43M ﹤0.01% 1809
2019
Q4 		$3.94M Buy
33,492
+13,118
+64% +$1.3M ﹤0.01% 2227
2019
Q3 		$1.75M Buy
20,374
+813
+4% +$61.5K ﹤0.01% 2720
2019
Q2 		$1.27M Sell
19,561
-11,034
-36% -$687K ﹤0.01% 2931
2019
Q1 		$1.91M Buy
30,595
+463
+2% +$21.8K ﹤0.01% 2692
2018
Q4 		$1.17M Buy
30,132
+72
+0.2% +$3.2K ﹤0.01% 2885
2018
Q3 		$1.71M Sell
30,060
-205
-0.7% -$12.8K ﹤0.01% 2818
2018
Q2 		$2.42M Buy
30,265
+4,956
+20% +$411K ﹤0.01% 2555
2018
Q1 		$2.19M Sell
25,309
-1,472
-5% -$119K ﹤0.01% 2559
2017
Q4 		$1.85M Sell
26,781
-20,993
-44% -$1.68M ﹤0.01% 2662
2017
Q3 		$4.34M Buy
47,774
+1,968
+4% +$168K ﹤0.01% 1968
2017
Q2 		$3.41M Sell
45,806
-11,923
-21% -$955K ﹤0.01% 2116
2017
Q1 		$5.41M Buy
57,729
+19,453
+51% +$1.76M 0.01% 1678
2016
Q4 		$2.78M Sell
38,276
-15,030
-28% -$1.29M ﹤0.01% 2145
2016
Q3 		$5.57M Sell
53,306
-2,223
-4% -$201K 0.01% 1457
2016
Q2 		$4.1M Sell
55,529
-15,844
-22% -$1.08M 0.01% 1716
2016
Q1 		$4.01M Buy
71,373
+50,382
+240% +$2.97M 0.01% 1787
2015
Q4 		$1.42M Buy
20,991
+6,617
+46% +$354K ﹤0.01% 2514
2015
Q3 		$416K Buy
14,374
+6,212
+76% +$301K ﹤0.01% 2811
2015
Q2 		$439K Buy
8,162
+61
+0.8% +$3.11K ﹤0.01% 3359
2015
Q1 		$388K Buy
8,101
+9
+0.1% +$391 ﹤0.01% 3421
2014
Q4 		$313K Buy
+8,092
New +$255K ﹤0.01% 3536

Other funds holding NVRO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Parametric Portfolio Associates's NVRO Position: Q1 2022 in Review

Parametric Portfolio Associates increased its NEVRO CORP. (NVRO) stake by 12% in Q1 2022, buying an estimated $399K and bringing the position to 49,990 shares worth $3.62M. The position accounts for ﹤0.01% of the portfolio, ranked #2072.

Parametric Portfolio Associates first reported a position in NVRO in Q4 2014 and has held it in 30 quarters since. The position peaked at $6M in Q4 2020. 195 funds tracked by Wall St. Rank hold NVRO as of Q1 2022.

  • Parametric Portfolio Associates held 49,990 shares of NEVRO CORP. worth $3.62M as of Q1 2022.
  • Parametric Portfolio Associates bought 5,539 NEVRO CORP. shares in Q1 2022, an estimated $399K.
  • NEVRO CORP. made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2072 holding.
  • Parametric Portfolio Associates first reported a position in NEVRO CORP. in Q4 2014 and has held it in 30 quarters since.
  • Parametric Portfolio Associates's NEVRO CORP. position peaked at $6M in Q4 2020.
  • 195 funds tracked by Wall St. Rank held NEVRO CORP. as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.